Related News
Watchdog says Abbott milk cleared all quality tests
By Dong Zhen |
March 27, 2012, Tuesday
|
Online Edition
Online Edition
THE Chinese imported food watchdog said today they had so far not discovered any substandard issues with an Abbott infant formula sold on domestic markets after a report released by a Hong Kong-based research firm on the weekend put its quality under question.
The report by CER Research stated that a sample of Abbott Similac Stage 1 formula milk for 0-6 months old babies purchased from a Hong Kong local store failed to meet Chinese mainland protein standards for such products.
The research firm said it had sent the sample, along with those of some other foreign formula brands, to be tested by a top professional lab in Germany. The results showed sub-standard issues with all samples while Abbott Similac Stage 1 turned out the worse performer.
The firm also claimed that the Abbott formula contained casein levels exceeding mainland standards and said this could cause diarrhea, intestinal bleeding and kidney problems in babies alongside malnutrition.
Abbott China hit back by calling the report "utterly and deliberately misleading." The formula provider is readying legal actions against the research firm and has already sent its milk samples to be tested by an independent lab certified by professional international quality authorities.
Shanghai Entry-Exit Inspection and Quarantine Bureau said today none of the Abbott Similac Stage 1 batches imported to the mainland market had failed domestic standards.
The Similac Stage 1 products sold on the mainland market are produced in Singapore, New Zealand, the Netherlands and Spain and imported through the Shanghai port, according to Abbott. All batches ever imported have passed quarantine checks and gained certifications issued by the quarantine watchdog, Abbott China said.
Mainland standards rule that the whey-to-casein ratio in infant formulas should be 60 to 40 percent with whey content being no less than 60 percent. But this specific standard covering the ratio is not mentioned under the Hong Kong watchdog rules.
The report by CER Research stated that a sample of Abbott Similac Stage 1 formula milk for 0-6 months old babies purchased from a Hong Kong local store failed to meet Chinese mainland protein standards for such products.
The research firm said it had sent the sample, along with those of some other foreign formula brands, to be tested by a top professional lab in Germany. The results showed sub-standard issues with all samples while Abbott Similac Stage 1 turned out the worse performer.
The firm also claimed that the Abbott formula contained casein levels exceeding mainland standards and said this could cause diarrhea, intestinal bleeding and kidney problems in babies alongside malnutrition.
Abbott China hit back by calling the report "utterly and deliberately misleading." The formula provider is readying legal actions against the research firm and has already sent its milk samples to be tested by an independent lab certified by professional international quality authorities.
Shanghai Entry-Exit Inspection and Quarantine Bureau said today none of the Abbott Similac Stage 1 batches imported to the mainland market had failed domestic standards.
The Similac Stage 1 products sold on the mainland market are produced in Singapore, New Zealand, the Netherlands and Spain and imported through the Shanghai port, according to Abbott. All batches ever imported have passed quarantine checks and gained certifications issued by the quarantine watchdog, Abbott China said.
Mainland standards rule that the whey-to-casein ratio in infant formulas should be 60 to 40 percent with whey content being no less than 60 percent. But this specific standard covering the ratio is not mentioned under the Hong Kong watchdog rules.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
